Tamsulosin and solifenacin combined therapy in patients with lower urinary tract symptoms – evidence-based indications and practical considerations Review article
Article Sidebar
Published:
Mar 31, 2024
Keywords:
benign prostate hyperplasia, frequence, urgency, tamsulosin, solifenacin, combined therapy
Main Article Content
Abstract
Tamsulosin with solifenacin is a common combination therapy in patients with predominant storage lower urinary tract symptoms (LUTS). In this group of patients LUTS can be secondary to benign prostate enlargement or appear without association with bladder outlet obstruction. Initial validation studies introduce tamsulosin with solifenacin as a safe combination. The selection of patients who will benefit most from duotherapy remains the crucial clinical aspect.
Article Details
How to Cite
Zapała, P. (2024). Tamsulosin and solifenacin combined therapy in patients with lower urinary tract symptoms – evidence-based indications and practical considerations. Medycyna Faktow (J EBM), 17(1(62), 110-114. https://doi.org/10.24292/01.MF.0124.17
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Chapple CR, Wein AJ, Abrams P et al. Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol. 2008; 54(3): 563-9.
2. Roosen A, Chapple CR, Dmochowski RR et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009; 56(5): 810-9.
3. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50(6): 1306-14; discussion 1314-5.
4. Chapple C, Herschorn S, Abrams P et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2009; 56(3): 534-41.
5. Lee HN, Lee KS, Kim JC et al. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms. Int J Clin Pract. 2015; 69(4): 444-53.
6. Athanasopoulos A, Gyftopoulos K, Giannitsas K et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003; 169(6): 2253-6.
7. Gacci M, Sebastianelli A, Salvi M et al. Tolterodine in the Treatment of Male LUTS. Curr Urol Rep. 2015; 16(9): 60.
8. Van Kerrebroeck P, Haab F, Angulo JC et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol. 2013; 64(3): 398-407.
9. Drake MJ, Chapple C, Sokol R et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. 2015; 67(2): 262-70.
10. Roehrborn CG, Kaplan SA, Kraus SR et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology. 2008; 72(5): 1061-7; discussion 1067.
11. Drake MJ, Bowditch S, Arbe E et al. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands. BMC Urol. 2017; 17(1): 36.
12. Athanasopoulos A, Chapple C, Fowler C et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol. 2011; 60(1): 94-105.
13. Kaplan SA, Roehrborn CG, Abrams P et al. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011; 65(4): 487-507.
14. Kim HJ, Sun HY, Choi H et al. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. PloS One. 2017; 12(1): e0169248.
15. van Kerrebroeck P, Chapple C, Drogendijk T et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013; 64(6): 1003-12.
16. EAU Guidelines: Management of Non-neurogenic Male LUTS. Uroweb.
17. Rees J, Foley S, Huang M et al. Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe. Neurourol Urodyn. 2019; 38(3): 981-9.
18. Burgio KL, Kraus SR, Johnson TM et al. Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men: A Randomized Clinical Trial. JAMA Intern Med. 2020; 180(3): 411-9.
19. Gong M, Dong W, Huang G et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin. 2015; 31(9): 1781-92.
20. Kaplan SA, Roehrborn CG, Rovner ES et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006; 296(19): 2319-28.
21. Drake MJ, Oelke M, Snijder R et al. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCASTM for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. PloS One. 2017; 12(2): e0170726.
22. Kaplan SA, He W, Koltun WD. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol. 2013; 63(1): 158-65.
23. İlhan B, Erdoğan T, Topinková E et al.; EuGMS Task and Finish Group on FRIDs. Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review. Eur Geriatr Med. 2023; 14(4): 733-46.
2. Roosen A, Chapple CR, Dmochowski RR et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009; 56(5): 810-9.
3. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50(6): 1306-14; discussion 1314-5.
4. Chapple C, Herschorn S, Abrams P et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2009; 56(3): 534-41.
5. Lee HN, Lee KS, Kim JC et al. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms. Int J Clin Pract. 2015; 69(4): 444-53.
6. Athanasopoulos A, Gyftopoulos K, Giannitsas K et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003; 169(6): 2253-6.
7. Gacci M, Sebastianelli A, Salvi M et al. Tolterodine in the Treatment of Male LUTS. Curr Urol Rep. 2015; 16(9): 60.
8. Van Kerrebroeck P, Haab F, Angulo JC et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol. 2013; 64(3): 398-407.
9. Drake MJ, Chapple C, Sokol R et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. 2015; 67(2): 262-70.
10. Roehrborn CG, Kaplan SA, Kraus SR et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology. 2008; 72(5): 1061-7; discussion 1067.
11. Drake MJ, Bowditch S, Arbe E et al. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands. BMC Urol. 2017; 17(1): 36.
12. Athanasopoulos A, Chapple C, Fowler C et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol. 2011; 60(1): 94-105.
13. Kaplan SA, Roehrborn CG, Abrams P et al. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011; 65(4): 487-507.
14. Kim HJ, Sun HY, Choi H et al. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. PloS One. 2017; 12(1): e0169248.
15. van Kerrebroeck P, Chapple C, Drogendijk T et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013; 64(6): 1003-12.
16. EAU Guidelines: Management of Non-neurogenic Male LUTS. Uroweb.
17. Rees J, Foley S, Huang M et al. Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe. Neurourol Urodyn. 2019; 38(3): 981-9.
18. Burgio KL, Kraus SR, Johnson TM et al. Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men: A Randomized Clinical Trial. JAMA Intern Med. 2020; 180(3): 411-9.
19. Gong M, Dong W, Huang G et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin. 2015; 31(9): 1781-92.
20. Kaplan SA, Roehrborn CG, Rovner ES et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006; 296(19): 2319-28.
21. Drake MJ, Oelke M, Snijder R et al. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCASTM for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. PloS One. 2017; 12(2): e0170726.
22. Kaplan SA, He W, Koltun WD. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol. 2013; 63(1): 158-65.
23. İlhan B, Erdoğan T, Topinková E et al.; EuGMS Task and Finish Group on FRIDs. Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review. Eur Geriatr Med. 2023; 14(4): 733-46.